Des Plaines

Abbott Expands Agreement with GSK to Include Development of a Companion Diagnostic Test for an Additional Investigational Cancer Immunotherapy Antigen

New Abbott Gene-Based Test for Colorectal Cancer Receives CE Mark

DES PLAINES, Illinois, November 28, 2011 - Abbott (NYSE: ABT)announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A.

MORE..

Older News

DES PLAINES, Illinois, January 6 - Abbott (NYSE: ABT) announced today it has received CE Marking (Conformite Europeene) in the European Union for a new molecular diagnostic test, Abbott RealTime mS9 Colorectal Cancer, a non-invasive DNA assay that detects the methylated form of Septin 9, a gene linked to colorectal cancer, in blood specimens.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy